IXICO plc IXICO selected by Cyclerion for a new AD study (7695Q)
02 Marzo 2021 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 7695Q
IXICO plc
02 March 2021
IXICO plc
("IXICO" or the "Company")
IXICO is selected by Cyclerion for a new Alzheimer's disease
study
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, announces that it has been selected by
Cyclerion Therapeutics, Inc., a new client, to support the
company's Phase IIa clinical trial to investigate CY6463 for
treatment of individuals with Alzheimer's disease . For the study,
IXICO will provide advanced neuroimaging solutions involving
structural magnetic resonance imaging (MRI), diffusion MRI (dMRI),
resting state functional MRI (rs-fMRI) and arterial spin labelling
(ASL).
Alzheimer's disease (AD) is a progressive degenerative disease
affecting approximately 50 million people worldwide with
devastating physical, emotional and financial impact to patients
and families. With no available therapies to address the underlying
disease pathology, new approaches are urgently needed, and
biopharmaceutical companies are responding with innovations in
clinical trials and treatment targets in their AD pipelines. This
new study will be looking at the role of vascular pathology in AD,
and more specifically, the potential of the NO-sGC-cGMP pathway as
a target for new AD therapies.
Whilst this contract does not change management's expectations
of financial performance for the year, it adds to the Company's
strong order book, further increases visibility of future revenues,
and reflects an increasing diversification of the Company's client
base.
Lammert Albers, Chief Commercial Officer of IXICO, commented: "
IXICO is thrilled to be chosen by Cyclerion Therapeutics and take
part in this important Alzheimer's disease trial. There are
currently no means to prevent or delay onset, slow progression or
meaningfully improve symptoms of this devastating disease. With
more than 120 unique investigational drugs in clinical trials,
IXICO is proud to support potential treatments that one day may be
in the hands of Alzheimer's patients worldwide."
Chris Wright, Chief Medical Officer at Cyclerion, said: "We are
pleased to leverage IXICO's neuroimaging services in this new
Alzheimer's disease study. With Cyclerion's mission to develop
treatments that restore cognitive function, it is very important
that our study is supported by world-class providers who are
specialist experts in CNS and Alzheimer's disease clinical trials.
We are delighted that IXICO will support us in measuring the impact
of the trialled treatment."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRGDXUDGDGBB
(END) Dow Jones Newswires
March 02, 2021 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024